Investors

Investors

Corporate Profile

We are a clinical-stage biopharmaceutical company developing innovative therapies for rare forms of cancer and orphan diseases.

Leveraging our proprietary ERYCAPS platform, which uses a novel technology to encapsulate therapeutic drug substances inside erythrocytes, or red blood cells, we have developed a pipeline of product candidates targeting markets with high unmet medical needs. Our initial focus is on the treatment of blood cancers, including acute lymphoblastic leukemia, or ALL, and acute myeloid leukemia, or AML, by depriving tumors of nutrients necessary for their survival, which is referred to as tumor starvation.

Stock Quote

Exchange
Price
Change (%)
Volume
Data as of
Exchange
Price
Change (%)
Volume
Data as of
More >>

Recent News

Date Title and Summary Additional Formats
Toggle Summary Avenant au Contrat de Liquidité
ERYTECH : Avenant au Contrat de Liquidité March 26, 2014 03:00 AM Eastern Daylight Time LYON, France--( BUSINESS WIRE )--Regulatory News: ERYTECH (Paris:ERYP) (Euronext Paris : FR0011471135 - ERYP), société biopharmaceutique française qui conçoit des traitements innovants contre les leucémies
View HTML
Toggle Summary Bilan semestriel du contrat de liquidité confié à la société de bourse Bryan, Garnier & Co.
ERYTECH Pharma : Bilan semestriel du contrat de liquidité confié à la société de bourse Bryan, Garnier & Co. July 02, 2014 12:00 PM Eastern Daylight Time LYON, France--( BUSINESS WIRE )--Regulatory News: ERYTECH Pharma (Paris:ERYP) (Euronext Paris : FR0011471135 - ERYP), société biopharmaceutique
View HTML
Toggle Summary CORRECTING and REPLACING: Erytech Pharma: Information Related to Total Number of Voting Rights and Shares Composing the Share Capital
December 2015 Article 223-16 of general regulation of French Autorité des Marchés Financiers LYON, France --(BUSINESS WIRE)--Feb. 4, 2016-- Regulatory News: This replaces the announcement made at 2:20 pm on January 12 due to the following corrections: The total of brut voting rights of 9 625 437 is
View HTML
Toggle Summary ERYTECH : ASSEMBLEE GENERALE MIXTE DU 17 JUIN 2014
ERYTECH : ASSEMBLEE GENERALE MIXTE DU 17 JUIN 2014 Modalités de mise à disposition des documents préparatoires May 27, 2014 03:48 PM Eastern Daylight Time LYON, France--( BUSINESS WIRE )--Regulatory News : ERYTECH Pharma (Paris:ERYP) (Euronext Paris : FR0011471135 - ERYP), la société
View HTML
More >>

Upcoming Events

There are currently no events to display.

RECEIVE E-MAIL ALERTS

Copyright West LLC. Minimum 15 minutes delayed.

Top